ArticleScandinavian journal of public health2025
Incidence of ADHD medication use among Finnish children and adolescents in 2008-2019: a need for practice changes?
Article in Scandinavian journal of public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 6 citations in OpenAlex.
- Trends in the incidence of attention deficit hyperactivity disorder in children and early risk factors.JCPP advances · 2026Article
- Prevalence, Trends and Patterns of ADHD Medication Use Among Children, Adolescents and Young Adults in Quebec, Canada: A Repeated Cross-Sectional Population-Based Study From 2000 to 2022: Prévalence, tendances et profils d'utilisation des médicaments pour le TDAH chez les enfants, les adolescents et les jeunes adultes au Québec (Canada) : étude populationnelle transversale répétée, 2000-2022.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2026Article
- Incidence of ADHD diagnoses and medication initiation among children and adolescents in Norway from 2016-2024.European child & adolescent psychiatry · 2026Article
- Trends in use of Attention-Deficit Hyperactivity Disorder medications among children and adults in five European countries, 2010 to 2023: a population-based observational study.The Lancet regional health. Europe · 2026Article
- Duration of ADHD medication treatment among Finnish children and adolescents ‒ a nationwide register study.European child & adolescent psychiatry · 2025Article
- Childhood family income and medication use in youth.Journal of epidemiology and community health · 2025Article
- Increase in Occurrence of Attention Deficit Hyperactivity Disorder Differs by Age Group and Gender-Finnish Nationwide Register Study.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study examined the incidence of attention-deficit/hyperactivity disorder medication among children and adolescents by sex and age group in Finland during 2008-2019.
methodsThe data on children and adolescents aged 6-18 years receiving reimbursement for any attention-deficit/hyperactivity disorder medication was collected from the nationwide register on reimbursed purchases. The incidence was calculated as a ratio of the number of new users and the number of age and sex-matched population at risk. Negative binomial models were used to calculate rate ratios (RRs).
resultsIn 2019, the incidence of attention-deficit/hyperactivity disorder medication was 13.4 per 1000 boys and 4.8 per 1000 girls. Among boys, the incidence became 3.7 times greater during the observed years (RR 95% confidence interval (CI) 2.0, 6.5,
conclusionsThe incidence of attention-deficit/hyperactivity disorder medication use among children and adolescents increased significantly in Finland during the study period. Incidence was higher among boys, but the increase was greater among girls. The most common group to start attention-deficit/hyperactivity disorder medication was 6-8-year-old boys. These findings warrant critical evaluation of the diagnostic and treatment policies currently available in Finland for the treatment of attention-deficit/hyperactivity disorder and related symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.